Sign in to view content

Intravitreal Gene Therapy for Neovascular AMD With ADVM-022: Results of the Phase 1 OPTIC Trial

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2020

Related

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Updates from the Field
2019
Defining and Addressing Wet AMD Non-responders
Rishi P. Singh, MD
Updates from the Field
2019

Category: AMD-Neovascular

See more